Loading...

PointBreak: A Randomized Phase III Study of Pemetrexed Plus Carboplatin and Bevacizumab Followed by Maintenance Pemetrexed and Bevacizumab Versus Paclitaxel Plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB or IV Nonsquamous Non–Small-Cell Lung Cancer

PURPOSE: PointBreak (A Study of Pemetrexed, Carboplatin and Bevacizumab in Patients With Nonsquamous Non-Small Cell Lung Cancer) compared the efficacy and safety of pemetrexed (Pem) plus carboplatin (C) plus bevacizumab (Bev) followed by pemetrexed plus bevacizumab (PemCBev) with paclitaxel (Pac) pl...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:J Clin Oncol
Main Authors: Patel, Jyoti D., Socinski, Mark A., Garon, Edward B., Reynolds, Craig H., Spigel, David R., Olsen, Mark R., Hermann, Robert C., Jotte, Robert M., Beck, Thaddeus, Richards, Donald A., Guba, Susan C., Liu, Jingyi, Frimodt-Moller, Bente, John, William J., Obasaju, Coleman K., Pennella, Eduardo J., Bonomi, Philip, Govindan, Ramaswamy
Format: Artigo
Sprog:Inglês
Udgivet: American Society of Clinical Oncology 2013
Fag:
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4881367/
https://ncbi.nlm.nih.gov/pubmed/24145346
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2012.47.9626
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!